Robert Michael

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.

Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ.

Founded in 2016, AbbVie Biotherapeutics Ltd. is a British company that functions as an investment holding company. Part of AbbVie, Inc., the private company is based in Maidenhead, UK.

Fremont Holding LLC engages in provision of pharmaceutical services. The company is headquartered in North Chicago, IL.

Part of AbbVie, Inc., AbbVie Ltd. (United Kingdom) is a British company that develops advanced therapies through research and innovation. The private company is based in Maidenhead, UK and was founded in 2012.